6-Ketoprostaglandin F1 alpha
"6-Ketoprostaglandin F1 alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.
| Descriptor ID |
D015121
|
| MeSH Number(s) |
D10.251.355.255.550.400.350 D10.251.355.325.450 D23.469.050.175.725.400.350
|
| Concept/Terms |
6-Ketoprostaglandin F1 alpha- 6-Ketoprostaglandin F1 alpha
- F1 alpha, 6-Ketoprostaglandin
- alpha, 6-Ketoprostaglandin F1
- 6-Oxoprostaglandin F1 alpha
- 6 Oxoprostaglandin F1 alpha
- F1 alpha, 6-Oxoprostaglandin
- alpha, 6-Oxoprostaglandin F1
- 6-Oxo-PGF1 alpha
- 6 Oxo PGF1 alpha
- alpha, 6-Oxo-PGF1
- 6 Ketoprostaglandin F1 alpha
- 6-Keto-PGF1 alpha
- 6 Keto PGF1 alpha
- alpha, 6-Keto-PGF1
|
Below are MeSH descriptors whose meaning is more general than "6-Ketoprostaglandin F1 alpha".
Below are MeSH descriptors whose meaning is more specific than "6-Ketoprostaglandin F1 alpha".
This graph shows the total number of publications written about "6-Ketoprostaglandin F1 alpha" by people in this website by year, and whether "6-Ketoprostaglandin F1 alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "6-Ketoprostaglandin F1 alpha" by people in Profiles.
-
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9):2078-85.
-
An active triple-catalytic hybrid enzyme engineered by linking cyclo-oxygenase isoform-1 to prostacyclin synthase that can constantly biosynthesize prostacyclin, the vascular protector. FEBS J. 2008 Dec; 275(23):5820-9.
-
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2436-46.
-
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H343-51.
-
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):72-9.
-
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007 Jun; 292(6):H2891-7.
-
Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions. Eur J Haematol. 2002 Mar; 68(3):163-9.
-
Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000 Aug 22; 102(8):840-5.
-
Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999 Jul; 94(7):1818-22.
-
Brief mesenteric ischemia increases PGE2, but not PGI2, in intestinal lymph of cats. Am J Physiol. 1994 May; 266(5 Pt 2):R1692-6.